Anvil Diagnostics

📍 Cambridge, United States🗓 Founded 2022👥 8 employees💰 Last funded Nov 2025
Biotechnology Research🌐 anvildiagnostics.com
Website LinkedIn
We are making a simple blood test to differentiate and quantify nearly all pathogen genes in hospitalized patients. Pathogen DNA is detectable at early stages of infection, and by quantifying it over time, we aim to change how infections are managed at every phase of care. The solution is “hidden in plain sight.” We enhance digital PCR hardware that hospitals are already starting to adopt with machine learning and programmable chemistry. Today, PCR tests have become routine but only for limited sets of pathogens. By making PCR both comprehensive and extremely sensitive, we will detect the range of pathogen genes at the "helix in the haystack" levels found in blood.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Anvil Diagnostics?
Anvil Diagnostics has 2 investors on record on gritt.io, 2 mid-stage.
When did Anvil Diagnostics last raise funding?
The most recent investment in Anvil Diagnostics recorded on gritt.io was in November 2025.
When was Anvil Diagnostics founded?
Anvil Diagnostics was founded in 2022.
What industry is Anvil Diagnostics in?
Anvil Diagnostics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Anvil Diagnostics based?
Anvil Diagnostics is headquartered in Cambridge, United States.